Abstract
Abstract Background: The quality of life for patients treated with the FOLFOX protocol can vary depending on the stage of their cancer and how they respond to treatment. Objectives: The current study aimed to assess the quality of life (QoL) and adherence to treatment in a sample of Iraqi patients diagnosed with colon cancer and treated with FOLFOX protocol. Patients and Methods: A cross-sectional study was conducted at the Oncology Teaching Hospital, Al-Amal National Hospital for Oncology, and Al-Imamain Al-Kadhimiyan Medical City. Fifty adult patients with histologically proven colon cancer receiving treatment with the FOLFOX protocol were recruited for this research. The European Organization for Research and Treatment of Cancer (EORTC QLQ-C30) and Morisky Medication-taking Adherence Scale (MMAS) were employed in this research. Results: It was observed that phlebitis 32 (64.0%) was the most common adverse event experienced after treatment with FOLFOX protocol, followed by neuropathy 27 (54.0%), nausea and vomiting 19 (38.0%), neutropenia 15 (30.0%), and diarrhea 12 (24.0%). Concerning participants adherence to treatment, according to MMAS-8 questionnaire, 27 (54%) had medium adherence and 19 (38%) had high adherence to treatment. Regarding the functional scales of EORTC QLQ-C30, role and emotional functioning were the most affected, with a lower mean than other scales. Among the symptoms scale of EORTC QLQ-C30; fatigue, nausea, vomiting, and appetite loss were the most distressing symptoms reported. Conclusion: Colon cancer’s rising incidence underscores its significant impact on patients, affecting daily activities and emotional well-being. This extends to treatment modalities such as the FOLFOX protocol, potentially influencing patients’ overall QoL.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call